3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow: A Phase II Study

Trial Profile

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow: A Phase II Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Monoclonal antibody 3F8 (Primary) ; Tretinoin (Primary)
  • Indications Cancer metastases; Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
    • 19 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 21 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top